0001415889-17-000182.txt : 20170203
0001415889-17-000182.hdr.sgml : 20170203
20170203185059
ACCESSION NUMBER: 0001415889-17-000182
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170201
FILED AS OF DATE: 20170203
DATE AS OF CHANGE: 20170203
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ACADIA PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001070494
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 061376651
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
BUSINESS PHONE: 858-558-2871
MAIL ADDRESS:
STREET 1: 3611 VALLEY CENTRE DRIVE
STREET 2: SUITE 300
CITY: SAN DIEGO
STATE: CA
ZIP: 92130
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Baity Glenn
CENTRAL INDEX KEY: 0001487100
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-50768
FILM NUMBER: 17573609
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD.
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4
1
form4-02032017_030250.xml
X0306
4
2017-02-01
0001070494
ACADIA PHARMACEUTICALS INC
ACAD
0001487100
Baity Glenn
3611 VALLEY CENTRE DRIVE, SUITE 300
SAN DIEGO
CA
92130
false
true
false
false
EVP AND GC
Common Stock
2017-02-01
4
M
0
21078
1.55
A
98141
D
Common Stock
2017-02-01
4
S
0
31078
35.1497
D
67063
D
Stock Option (right to buy)
1.55
2017-02-01
4
M
0
21078
0
D
2020-03-11
Common Stock
21078
0
D
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2016.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.10 to $35.315 per share, inclusive.The reporting person undertakes to provide ACADIA Pharmaceuticals Inc., any security holder of ACADIA Pharmaceuticals Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the foregoing range.
25% of the shares subject to the Stock Option vested and became exercisable on March 12, 2011. The remaining shares vested and became exercisable thereafter in 36 equal monthly installments.
/s/ Elizabeth Carter, Attorney-in-Fact
2017-02-03